Algorithm for Use on Eight Types of Cancer Trained on Seven Scanner Models
Gestalt Diagnostics is proud to announce our latest release – an AI algorithm for use on one of the broadest trained environments for commercial or research use. The Mitotic Counting algorithm was trained on over 100,000 individual mitosis and across seven scanner models. The algorithm boasts an F1-Score of 0.74, which is tantamount to the best state-of-the-art methods.
This algorithm is available today in the Gestalt AI Studio™ and for use on – Cutaneous mast cell tumor, breast cancer, lymphoma, lung cancer, melanoma, neuroendocrine, colon cancer, and bladder carcinoma. It has been trained on various models of Hamamatsu, Leica, 3D Histech and Aperio scanners.
The defining factor for the broad applicability of deep learning models is their capability to generalize to unseen scanners and tissue types; a comprehensive dataset is essential to achieving this goal. The data set we employed covers seven tissue types spanning eight tumors and is digitized with seven scanners.
Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer, asks: “What does this mean for our customers? Confidence. Gestalt is focused on providing solutions that provide a foundation of confidence in use as this industry continues to evolve, innovate, and incorporate products that are meant to enhance a pathologist’s or scientist’s daily life.”
“We are extremely proud of the comprehensive approach we take to AI development as an organization. Our position is to not only look at development and training with a small subset of images or on one or two scanners, that would not prove as effective or accurate as we feel our customers and the industry require. Therefore, we train on tens of thousands images, tumors cells, or in this case, mitosis and multiple scanner models across several scanner vendors to ensure the most accurate, clinically usable options for our customers,” says Brian Napora, Gestalt VP, AI Solutions.
Gestalt Diagnostics, Inc.
Gestalt Diagnostics transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. Our platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing invaluable expertise where it matters most. To learn more, visit www.gestaltdiagnostics.com and follow Gestalt on LinkedIn and @Gestalt122 on Twitter. Research Use Only (RUO) unless following CAP guidelines for LDT.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
